Evidence map›Paper›PMID 32310062›Full record

ArticleEmerging infectious diseases2020

Nationwide Monitoring for Plasmodium falciparum Drug-Resistance Alleles to Chloroquine, Sulfadoxine, and Pyrimethamine, Haiti, 2016-2017.

Eric Rogier, Camelia Herman, Curtis S Huber, Karen E S Hamre, Baby Pierre, Kimberly E Mace, Jacquelin Présumé, Gina Mondélus, Ithamare Romilus, Tamara Elismé and 7 more

Abstract read
In one paragraph

Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Molecules (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Investigations of socioeconomic factors associated with follow-up compliance with malaria treatment in Haiti.Revista panamericana de salud publica = Pan American journal of public health · 2021
    Article
  10. Establishing a National Molecular Surveillance Program for the Detection ofThe American journal of tropical medicine and hygiene · 2020
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Eric Rogier
Camelia Herman
Curtis S Huber
Karen E S Hamre
Baby Pierre
Kimberly E Mace
Jacquelin Présumé
Gina Mondélus
Ithamare Romilus
Tamara Elismé
Thomas P Eisele
Thomas Druetz
Alexandre Existe
Jacques Boncy
Jean F Lemoine
Venkatachalam Udhayakumar
Michelle A Chang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haiti is striving for zero local malaria transmission by the year 2025. Chloroquine remains the first-line treatment, and sulfadoxine/pyrimethamine (SP) has been used for mass drug-administration pilot programs. In March 2016, nationwide molecular surveillance was initiated to assess molecular resistance signatures for chloroquine and SP. For 778 samples collected through December 2017, we used Sanger sequencing to investigate putative resistance markers to chloroquine (Pfcrt codons 72, 74, 75, and 76), sulfadoxine (Pfdhps codons 436, 437, 540, 581, 613), and pyrimethamine (Pfdhfr codons 50, 51, 59, 108, 164). No parasites harbored Pfcrt point mutations. Prevalence of the Pfdhfr S108N single mutation was 47%, and we found the triple mutant Pfdhfr haplotype (108N, 51I, and 59R) in a single isolate. We observed no Pfdhps variants except in 1 isolate (A437G mutation). These data confirm the lack of highly resistant chloroquine and SP alleles in Haiti and support the continued use of chloroquine and SP.

Indexed as

AntimalarialsMalaria, FalciparumAllelesChloroquineDrug ResistanceHaitiHumansMutationPlasmodium falciparumPyrimethamineSulfadoxineAntimalarialsChloroquinePyrimethamineSulfadoxinechloroquinedrug resistanceHaitimalariaparasitesPlasmodium falciparumpyrimethaminesulfadoxine

Identifiers

PMID32310062
PMCPMC7181918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.